CYFRA 21-1 Test
CYFRA 21-1 Test: Lung Cancer Marker
Direct answer: The CYFRA 21-1 test measures fragments of cytokeratin-19 protein in blood to help detect and monitor lung cancer, especially non-small cell lung cancer.
CYFRA 21-1 is a tumour marker released when abnormal lung cells break down. Elevated levels may indicate lung cancer presence or recurrence. This test is commonly advised when symptoms such as persistent cough, shortness of breath or chest discomfort are present, or when imaging shows a suspicious lung mass. Sample collection is available through our Home Collection Facility across Pune or at our Direct Walk-in Facility in Aundh and nearby areas.
Why is the CYFRA 21-1 test advised?
Direct answer: This test helps detect lung cancer, monitor treatment response and identify possible recurrence.
Doctors interpret CYFRA 21–1 results along with imaging and other investigations to assess disease progression. Learn more about cancer-related testing in our health articles, check sample guidance in test preparation guides, or compare preventive health profiles on comparison resources.
Clinical reference
For external medical information on CYFRA 21-1 in lung cancer, visit the NCBI tumour marker reference.
Frequently Asked Questions
When should I do a CYFRA 21-1 test?
This test is advised when lung cancer is suspected due to symptoms or abnormal lung imaging findings.
Is fasting required before this test?
Fasting is not required. You may follow your normal diet before sample collection.
What does a high CYFRA 21-1 level indicate?
High levels usually suggest lung cancer activity or possible recurrence and require medical evaluation.
Which symptoms may lead to this test?
Persistent cough, breathlessness, chest pain or unexplained weight loss may prompt this test.
Medical Disclaimer: This content is for educational purposes only and does not replace professional medical advice. Test interpretation and clinical decisions must be confirmed with a qualified healthcare provider. Read the full policy at disclaimer policy.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
CYFRA 21-1 Test: Lung Cancer Marker
Direct answer: The CYFRA 21-1 test measures fragments of cytokeratin-19 protein in blood to help detect and monitor lung cancer, especially non-small cell lung cancer.
CYFRA 21-1 is a tumour marker released when abnormal lung cells break down. Elevated levels may indicate lung cancer presence or recurrence. This test is commonly advised when symptoms such as persistent cough, shortness of breath or chest discomfort are present, or when imaging shows a suspicious lung mass. Sample collection is available through our Home Collection Facility across Pune or at our Direct Walk-in Facility in Aundh and nearby areas.
Why is the CYFRA 21-1 test advised?
Direct answer: This test helps detect lung cancer, monitor treatment response and identify possible recurrence.
Doctors interpret CYFRA 21–1 results along with imaging and other investigations to assess disease progression. Learn more about cancer-related testing in our health articles, check sample guidance in test preparation guides, or compare preventive health profiles on comparison resources.
Clinical reference
For external medical information on CYFRA 21-1 in lung cancer, visit the NCBI tumour marker reference.
Frequently Asked Questions
When should I do a CYFRA 21-1 test?
This test is advised when lung cancer is suspected due to symptoms or abnormal lung imaging findings.
Is fasting required before this test?
Fasting is not required. You may follow your normal diet before sample collection.
What does a high CYFRA 21-1 level indicate?
High levels usually suggest lung cancer activity or possible recurrence and require medical evaluation.
Which symptoms may lead to this test?
Persistent cough, breathlessness, chest pain or unexplained weight loss may prompt this test.
Medical Disclaimer: This content is for educational purposes only and does not replace professional medical advice. Test interpretation and clinical decisions must be confirmed with a qualified healthcare provider. Read the full policy at disclaimer policy.
